Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Publication|Articles|June 16, 2025
Pharmacy Practice in Focus: Oncology
- June 2025
- Volume 7
- Issue 4
Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Advertisement
Advertisement
Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. Although the use of colony-stimulating factors (CSFs) is well established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
Advertisement
Advertisement